Latest Posts
About This Stock
More About This Stock
Read
Read
Read
Read
Read
Week In Review: China's Luxin Invests In $215 Million Funding For Intarcia's Long-Term Diabetes Device
Zacks' Jason Napodano Is Not Focused On A Biotech Bubble
Article By:
The Life Sciences Report
Thursday, July 9, 2015 8:45 AM EDT
Jason Napodano, CFA, of Zacks Investment Research details the upside for small-cap biotech names that he believes will be huge gainers for investor portfolios.
In this article: BCLI, CUR, CYNAF, GSK, NVIV Also: NBI, ACOR, AMGN, BIIB, BLUE, CELG, DEPO, GILD, IBB, JUNO, KITE, LLY, MD, PFE, RVXCF, D-STEM (DEFUNCT), SYK
Neuralstem Tanks 30% After Announcing Phase 2 Results For ALS Treatment
Article By:
Terry Chrisomalis
Friday, March 13, 2015 7:37 PM EDT
Neuralstem reported safety and partial efficacy results using their stem cell treatment NSI-566 for ALS
In this article: CUR
GTX: This Wearable Tech Company Could Deliver 6X Short-term Returns
Article By:
John H. Ford
Tuesday, February 24, 2015 11:42 AM EDT
GTX is the best pure play investment in the wearable tech sector, and the most undervalued company I have ever encountered, trading at an 85% discount to fair value.
In this article: GTXO, AAPL, GOOG, META, DGLY, WDAY, SPLK, LOJN, NMRX, BLUE, TRMB, MSLP, CUR, ISR, GOOGL
Convert Catalysts Into Profits: Sagient Research's Edward Stopke
Article By:
The Life Sciences Report
Friday, January 23, 2015 5:48 PM EDT
The biotech sector is teeming with companies racing to bring the hot new drug or therapy to the marketplace. Edward Stopke of Sagient Research unveils his list of companies with catalytic moments in the making.
In this article: PSTV, VCEL, ATHX, BLUE, CUR, KITE, NVS, AMGN, JUNO, RNN, MRK, ESALF, RPTP, CLDX, SRPT, PTCT, GILD, RMTI